BridgeBio Pharma Inc. has published a corporate presentation outlining its recent advancements and ongoing clinical trials. The company has successfully completed enrollment for three Phase 3 trials: one assessing BBP-418 for Limb-Girdle Muscular Dystrophy 2I/R9 with 112 patients, another evaluating encaleret in Autosomal Dominant Hypocalcemia Type 1 with 71 patients, and a third trial involving 114 participants to evaluate infigratinib in Achondroplasia. Additionally, BridgeBio has received FDA approval in the US for ATTR-CM and approvals in the EU, Japan, and the UK. The presentation highlights BridgeBio's focus on rapid decision-making and strategic financing to target genetic diseases effectively. You can access the full presentation through the link below.